Abstract
Large doses of omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are used to treat several diseases including hypertriglyceridemia in humans. Modest levels of EPA and DHA may be obtained from food, particularly from fatty fish. This review presents the literature examining the differences between omega-3 fatty acid dietary supplementation and prescribed omega-3-acid ethyl esters (P-OM3). Reports published between 1995 and 2007 containing sources, recommended intake, and differences in the various formulations of omega-3 fatty acids were sought in PubMed and the Food and Drug Administration (FDA) Websites. However, lack of head-to-head clinical trials using both P-OM3 and dietary-supplement omega-3 fatty acids is the greatest limitation of this review. Although many kinds of omega-3 fatty acid dietary supplements are available, the efficacy, quality, and safety of these products are questionable because they are beyond any pharmaceutical control. Thus, P-OM3 is the only FDA approved omega-3 fatty acid product which is available in the United States as an adjunct to diet to improve human health.
Keywords: Omega-3 fatty acids, diet, supplementation, triglycerides
Current Pharmaceutical Design
Title: PUFA for Human Health: Diet or Supplementation?
Volume: 15 Issue: 36
Author(s): P. Abete, G. Testa, G. Galizia, D. Della-Morte, F. Cacciatore and F. Rengo
Affiliation:
Keywords: Omega-3 fatty acids, diet, supplementation, triglycerides
Abstract: Large doses of omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are used to treat several diseases including hypertriglyceridemia in humans. Modest levels of EPA and DHA may be obtained from food, particularly from fatty fish. This review presents the literature examining the differences between omega-3 fatty acid dietary supplementation and prescribed omega-3-acid ethyl esters (P-OM3). Reports published between 1995 and 2007 containing sources, recommended intake, and differences in the various formulations of omega-3 fatty acids were sought in PubMed and the Food and Drug Administration (FDA) Websites. However, lack of head-to-head clinical trials using both P-OM3 and dietary-supplement omega-3 fatty acids is the greatest limitation of this review. Although many kinds of omega-3 fatty acid dietary supplements are available, the efficacy, quality, and safety of these products are questionable because they are beyond any pharmaceutical control. Thus, P-OM3 is the only FDA approved omega-3 fatty acid product which is available in the United States as an adjunct to diet to improve human health.
Export Options
About this article
Cite this article as:
Abete P., Testa G., Galizia G., Della-Morte D., Cacciatore F. and Rengo F., PUFA for Human Health: Diet or Supplementation?, Current Pharmaceutical Design 2009; 15 (36) . https://dx.doi.org/10.2174/138161209789909665
DOI https://dx.doi.org/10.2174/138161209789909665 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Assessment and Relevance of Carotid Intima-Media Thickness (C-IMT) in Primary and Secondary Cardiovascular Prevention
Current Pharmaceutical Design Interindividual Variability in the Efficacy of Oral Antiplatelet Drugs: Definitions, Mechanisms and Clinical Importance
Current Pharmaceutical Design The Bioactive Compounds Obtained from Hawthorn, Chokeberry, Rosehip and Bilberry by Microfiltration
Current Bioactive Compounds Statins Attenuate Fibrotic Manifestations of Cardiac Tissue Damage
Current Molecular Pharmacology Small Molecules Modulating Biogenesis or Processing of microRNAs with Therapeutic Potentials
Current Medicinal Chemistry Getting Patients to Target- Implementing the Guidelines
Current Vascular Pharmacology Exploration of Epigenetic State Hyperdopaminergia (Surfeit) and Genetic Trait Hypodopaminergia (Deficit) during Adolescent Brain Development
Current Psychopharmacology Simultaneous Determination of Six Components in Jingzhiguanxin Tablet by High-Performance Liquid Chromatography
Current Pharmaceutical Analysis Imaging and Laboratory Biomarkers in Cardiovascular Disease
Current Pharmaceutical Design Nutraceutical: A Drug, Dietary Supplement and Food Ingredient
Current Pharmacogenomics and Personalized Medicine Biological Signals Sensing with Wearable Technologies and an ECG Athlete Design
Recent Patents on Biomedical Engineering (Discontinued) Novel Approaches to the Pharmacotherapy of Obesity
Current Pharmaceutical Design Reverse Pharmacognosy: Another Way to Harness the Generosity of Nature
Current Pharmaceutical Design Coagulation Factor Xa Inhibition: Biological Background and Rationale
Current Topics in Medicinal Chemistry Perinatal Management of Fetal Tumors
Current Pediatric Reviews The Brain-Immune-Gut Triangle: Innate Immunity in Psychiatric and Neurological Disorders
Current Immunology Reviews (Discontinued) High-Density Lipoprotein Quantity or Quality for Cardiovascular Prevention?
Current Pharmaceutical Design Chemical and Biological Properties of Phenolics in Wine: Analytical Determinations and Health Benefits
Current Organic Chemistry Premature Cardiovascular Disease in Women with Lupus and Relationship to Disease Severity
Current Women`s Health Reviews The Cost-Effectiveness of Palivizumab in the Prevention of Respiratory Syncytial Virus Bronchiolitis: A Systematic Review
Current Respiratory Medicine Reviews